Evidence map›Paper›PMID 33738618›Full record

ReviewEJNMMI radiopharmacy and chemistry2021

Highlight selection of radiochemistry and radiopharmacy developments by editorial board.

Silvio Aime, Mohammed Al-Qahtani, Martin Behe, Guy Bormans, Giuseppe Carlucci, Jean N DaSilva, Clemens Decristoforo, Adriano Duatti, Philip H Elsinga, Klaus Kopka and 13 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in EJNMMI radiopharmacy and chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Silvio AimeUniversity of Torino, Torino, Italy.
Mohammed Al-QahtaniKing Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
Martin BehePaul Scherrer Institute, Villigen, Switzerland.
Guy BormansKatholieke Universiteit Leuven, Leuven, Belgium.
Giuseppe CarlucciUCLA Molecular and Medical Pharmacology Department, Los Angeles, USA.
Jean N DaSilvaUniversity of Montreal, Montreal, Canada.
Clemens DecristoforoUniversitaetsklinikum fur Nuclearmedizin, Innsbruck, Austria.
Adriano DuattiUniversity of Ferrara, Ferrara, Italy.
Philip H ElsingaUniversity Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Klaus KopkaHelmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany. k.kopka@hzdr.de.ORCID http://orcid.org/0000-0003-4846-1271
Xiang-Guo LiTurku PET-center, Turku, Finland.
Zhibo LiuPeking University, Beijing, China.
Robert H MachUniversity of Pennsylvania, Philadelphia, USA.
Oskar MiddelSt. Olavs Hospital, Trondheim, Norway.
Jan PasschierInvicro, London, UK.
Marianne PattUniversity of Leipzig, Leipzig, Germany.
Ivan PenuelasUniversity Clinic of Navarra, Pamplona, Spain.
Ana ReyUniversidad de la Republica, Montevideo, Uruguay.
Peter J H ScottUniversity of Michigan, Ann Arbor, USA.
Sergio ToddeUniversity of Milano-Bicoccia, Milan, Italy.
Jun ToyoharaTokyo Metropolitan Institute of Gerontology, Tokyo, Japan.
Danielle VugtsAmsterdam UMC, Amsterdam, The Netherlands.
Zhi YangPeking University Cancer Hospital, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biyearly highlight commentary to update the readership on trends in the field of radiopharmaceutical development.

resultsThis commentary of highlights has resulted in 23 different topics selected by each member of the Editorial Board addressing a variety of aspects ranging from novel radiochemistry to first in man application of novel radiopharmaceuticals.

conclusionTrends in radiochemistry and radiopharmacy are highlighted demonstrating the progress in the research field being the scope of EJNMMI Radiopharmacy and Chemistry.

Identifiers

PMID33738618
PMCPMC7973323

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.